STOCK TITAN
  1. Home
  2. News
  3. ANIK

Anika Therapeutics Inc. - ANIK STOCK NEWS

Welcome to our dedicated news page for Anika Therapeutics (Ticker: ANIK), a resource for investors and traders seeking the latest updates and insights on Anika Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Anika Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Anika Therapeutics's position in the market.

News
Anika to Issue First Quarter 2024 Financial Results on Wednesday, May 8, 2024
Rhea-AI Summary
Anika Therapeutics, Inc. (NASDAQ: ANIK) will release its first quarter 2024 financial results on May 8, 2024, followed by an investor conference call to discuss business highlights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Anika to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Anika Therapeutics, Inc. to participate in the 23rd Annual Needham Virtual Healthcare Conference on April 8, 2024. Virtual presentation with Q&A session to be hosted at 2:15pm ET. Webcast and archive available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
conferences
-
News
Anika Reports Fourth Quarter and Year-End 2023 Financial Results
Rhea-AI Summary
Anika Therapeutics, Inc. (ANIK) reports strong financial results for Q4 and full year 2023, with revenue growth exceeding expectations. The company achieved record annual revenues of $102 million, up 11% in 2023. Anika anticipates generating adjusted EBITDA of $25 to $30 million in 2024, a significant increase. Despite a non-recurring impairment charge, the company is optimistic about its performance and cost reduction initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.39%
Tags
earnings
News
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Anika Therapeutics, Inc. granted 2,500 non-statutory stock options to a newly hired non-executive employee at an exercise price of $25.14 per share, aligning with the market closing price on the grant date. The options will vest over three years, contingent on the grantee's continuous service, and will expire on the tenth anniversary of the grant date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
none
-
News
Anika to Issue Fourth Quarter and Year-End 2023 Financial Results on Wednesday, March 13, 2024
Rhea-AI Summary
Anika Therapeutics, Inc. (ANIK) will release its fourth quarter and year-end 2023 financial results on March 13, 2024. The investor conference call will discuss financial results and business highlights. Access the call via phone or webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.94%
Tags
earnings
-
News
Anika Highlights Its Recently Launched Integrity™ Implant System and RevoMotion™ Reverse Shoulder Arthroplasty System Along with Other Key Regenerative Products During the 2024 AAOS Annual Meeting
Rhea-AI Summary
Anika Therapeutics, Inc. announces the limited market release of X-Twist™ Fixation System with biocomposite suture anchor for rotator cuff and soft tissue repair at AAOS. The company highlights its Regenerative, Sports Medicine, and Arthrosurface Joint Solutions portfolio, including the Integrity Implant System, RevoMotion Reverse Shoulder Arthroplasty System, and AIM surgical planning software. Anika aims to provide surgeons with advanced regenerative technology and bone-preserving implant solutions to support patient recovery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.92%
Tags
none
News
Anika Announces First Surgeries Performed using the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Patch System for Rotator Cuff Repairs, Commencing Limited Market Release
Rhea-AI Summary
Anika Therapeutics, Inc. (ANIK) successfully enters the U.S. rotator cuff augmentation market with its Integrity Implant System, designed to protect injured tendons and promote healing. The system was cleared by the FDA in August 2023, and the first surgeries were successfully performed ahead of schedule. The implant's regenerative capacity and strength were validated in independent animal studies, positioning it as a game changer for surgeons and patients. The U.S. rotator cuff augmentation market is estimated to grow at a nearly 7% CAGR over the next 5 years, representing a high opportunity space in orthopedics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.27%
Tags
none
-
News
Anika to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Anika Therapeutics, Inc. (NASDAQ: ANIK) to participate in investor conferences at Stephens Annual Investment Conference and Piper Sandler 35th Annual Healthcare Conference. Dr. Cheryl Blanchard and Michael Levitz will present live and host 1x1 investor meetings. Webcasts and presentation archives available on Anika's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
conferences
-
News
Anika Reports Third Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance on Growing Momentum Across the Business
Rhea-AI Summary
Anika Therapeutics, Inc. reported strong financial results for Q3 2023, with revenue of $41.5 million, up 3% YoY. Joint Preservation and Restoration revenue increased by 14% and OA Pain Management revenue increased by 2%. The company launched the RevoMotion Reverse Shoulder Arthroplasty System and received FDA clearance for the Integrity Implant System and X-Twist Biocomposite Fixation System. Anika's net loss was ($6.6) million, compared to ($4.2) million in the prior year period. The company's adjusted net income was breakeven. Anika raised its revenue outlook for fiscal year 2023 to between $164 million and $166 million, representing 5% to 6% growth compared to 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.22%
Tags
earnings
News
Anika to Issue Third Quarter 2023 Financial Results on Thursday, November 2, 2023
Rhea-AI Summary
Anika Therapeutics, Inc. (NASDAQ: ANIK) to release Q3 2023 financial results on November 2, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
earnings
Stock ANIK logo
Anika Therapeutics Inc.

Nasdaq:ANIK

ANIK Rankings

#3206 Ranked by Market Cap
#4096 Ranked by Stock Gains
N/A Ranked by Dividends

ANIK Stock Data

378.82M
10.68M
3.25%
94.21%
5.19%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Bedford

About ANIK

who we are we are anika therapeutics, a global medical technology company at the forefront of pain management, tissue regeneration and wound healing. we are committed to delivering innovative medical solutions that help patients feel better faster, look and feel younger and remain active. with over 7 million procedures performed over the past twenty years utilizing our proprietary technology, anika is helping individuals all over the world return to life naturally. our guiding principles we are innovators and creators. we value strong discipline and exceptional focus from our personnel, and we employ lean principles and agile processes in managing our business. this foundation of guiding values, combined with our entrepreneurial spirit, gives anika the ability and fortitude to generate innovative ideas and to grow our portfolio of successful products. what we do anika offers a broad spectrum of therapeutic treatments ranging from pain management and tissue regeneration to wound care an